CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

CAR.AU

39.48

+0.61%↑

WOR.AU

14.64

+0.55%↑

AZJ.AU

3.19

+0.31%↑

RSG.AU

0.69

0%↓

Search

CSL Ltd

Uždarymo kaina

SektoriusPramonės sektorius

210.17 0.15

Apžvalga

Akcijų kainos pasikeitimas

24 val.

Dabar

Min

209.19

Max

210.4

Pagrindiniai rodikliai

By Trading Economics

Pajamos

2B

Pardavimai

-5.7B

2.5B

P/E

Sektoriaus vid.

21.941

38.367

Pelnas, tenkantis vienai akcijai

2.04

Dividendų pajamingumas

1.39

Pelno marža

24.437

Darbuotojai

29,904

EBITDA

-2.4B

858M

Rekomendacijos

By TipRanks

Rekomendacijos

Pirkti

12 mėnesių prognozė

+35.44% upside

Dividendai

By Dow Jones

Dividendų pajamingumas

Sektoriaus vid.

1.39%

2.26%

Rinkos statistika

By TradingEconomics

Rinkos kapitalizacija

-24B

100B

Ankstesnė atidarymo kaina

210.02

Ankstesnė uždarymo kaina

210.17

Naujienos nuotaikos

By Acuity

38%

62%

142 / 459 reitingas Industrials

CSL Ltd Grafikas

Ankstesni rezultatai nėra patikimas būsimų rezultatų rodiklis.

Susijusios naujienos

2025-08-19 03:32; UTC

Pagrindinės rinkos jėgos

CSL Shares Slide 13% After Earnings, Seqirus Spin-Off Announcement

2025-08-18 23:46; UTC

Uždarbis

CSL to Spin Off Seqirus, Cut Up to 15% of Staff in Sweeping Restructure -- Update

2025-08-18 22:15; UTC

Uždarbis

CSL to Cut Up to 15% of Staff in $770 Million Restructure

2025-04-09 09:39; UTC

Pagrindinės rinkos jėgos

Pharma Stocks Tumble After Trump Threatens Tariffs on Medicines

2025-02-10 21:55; UTC

Uždarbis

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025-02-10 21:34; UTC

Uždarbis

CSL Lifts 1st Half Net Profit by 3%, Led by Blood-Plasma Business

2025-08-18 23:46; UTC

Rinkos pokalbiai
Uždarbis

Investors May Have Lukewarm Reception to CSL's Earnings, Restructure -- Market Talk

2025-08-18 21:52; UTC

Uždarbis

CSL to Record Up to $700M-$770M in FY26 Restructuring Costs>CSL.AU

2025-08-18 21:51; UTC

Uždarbis

CSL to Cut Up to 15% of Staff>CSL.AU

2025-08-18 21:49; UTC

Uždarbis

CSL Says It Closed 22 Underperforming U.S. Plasma Centers in August>CSL.AU

2025-08-18 21:49; UTC

Uždarbis

CSL: Combination Will Deliver Synergies, Revenue Growth Opportunities>CSL.AU

2025-08-18 21:48; UTC

Uždarbis

CSL to Combine Behring and Vifor Medical and Commercial Functions>CSL.AU

2025-08-18 21:47; UTC

Uždarbis

CSL to Integrate R&D, Business Development, Commercial Teams>CSL.AU

2025-08-18 21:46; UTC

Uždarbis

CSL: Transformational Initiatives to Reduce Costs, Simplfy Decision Making>CSL.AU

2025-08-18 21:45; UTC

Uždarbis

CSL to Launch Multiyear Share Buyback in Fiscal 2026>CSL.AU

2025-08-18 21:45; UTC

Uždarbis

CSL Intends Seqirus to Be Listed on the ASX>CSL.AU

2025-08-18 21:44; UTC

Uždarbis

CSL Intends to Demerge Seqirus by End of FY 2026>CSL.AU

2025-08-18 21:43; UTC

Uždarbis

CSL Raises Dividend to $1.62 Vs. $1.45 >CSL.AU

2025-08-18 21:43; UTC

Uždarbis

CSL FY Underlying Net Profit $3.22B Vs. $2.91B>CSL.AU

2025-08-18 21:42; UTC

Uždarbis

CSL FY Rev $15.56B Vs. $14.80B >CSL.AU

2025-08-18 21:42; UTC

Uždarbis

CSL FY Net $3.00B Vs. Net $2.64B >CSL.AU

2025-06-17 02:15; UTC

Rinkos pokalbiai

Higher Margins Offered by CSL's Andembry Will Lift Earnings -- Market Talk

2025-04-09 07:01; UTC

Rinkos pokalbiai

CSL May Need to Raise Prices to Offset Trump's Potential Pharma Tariffs -- Market Talk

2025-03-21 02:03; UTC

Rinkos pokalbiai

Severe U.S. Influenza Season Could Benefit CSL -- Market Talk

2025-02-11 22:30; UTC

Rinkos pokalbiai

Flu Vaccines Proving Problematic for CSL -- Market Talk

2025-02-10 21:40; UTC

Uždarbis

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business -- Update

2025-02-10 21:19; UTC

Uždarbis

CSL Lifts 1H Net Profit by 3%, Led by Blood-Plasma Business

2025-02-10 21:13; UTC

Uždarbis

CSL Reaffirms Guidance for FY 2025 Net Profit of US$3.2 Billion-US$3.3 Billion at Constant FX

2025-02-10 21:12; UTC

Uždarbis

CSL Interim Dividend US$1.30/Security

2025-02-10 21:12; UTC

Uždarbis

CSL 1H Revenue US$8.48 Billion, Up 5% on Year

Akcijų palyginimas

Kainos pokytis

CSL Ltd Prognozė

Kainos tikslas

By TipRanks

35.44% į viršų

12 mėnesių prognozė

Vidutinis 283.415 AUD  35.44%

Aukščiausias 330 AUD

Žemiausias 227.5 AUD

Remiantis 13 „Wall Street“ analitikais, siūlančiais 12 mėnesių tikslines CSL Ltd kainas – Dist per pastaruosius 3 mėnesius.

Bendras įvertinimas

By TipRanks

Pirkti

13 ratings

9

Pirkti

4

Laikyti

0

Parduoti

Rinkos nuotaikos

By Acuity

142 / 459 reitingas Pramonės sektorius

Naujienos nuotaikos

Bulių rinkos įrodymas

Svyravimai

Žemiau vidurkio

Naujienų apimtis (RCV)

Aukščiau vidurkio

Finansinės naujienos

Pardavimo ir administravimo išlaidos

Veiklos sąnaudos

Ikimokestinis pelnas

Pardavimai

Pardavimo savikaina

Bendrasis pelnas iš pardavimo

Skolų palūkanų išlaidos

EBITDA

Veiklos pelnas

$

Apie bendrovę CSL Ltd

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally. The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants. The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology. The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.
help-icon Live chat